Once valid protocols for measurement of oxytocin have been established, multi-centre studies measuring oxytocin concentrations in craniopharyngioma and its relationship with neurobehavioural outcomes, eating behaviours, and metabolic outcomes may delineate which subgroups are at greater risk of presenting oxytocin dysregulation. This evidence concerns the gene OXT and craniopharyngioma.